Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Grows By 38.6%

SOPHiA GENETICS SA (NASDAQ:SOPH) was the target of a large increase in short interest in the month of December. As of December 15th, there was short interest totalling 37,000 shares, an increase of 38.6% from the November 30th total of 26,700 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 24,300 shares, the days-to-cover ratio is presently 1.5 days.

Analyst Ratings Changes

Separately, Craig Hallum began coverage on shares of SOPHiA GENETICS in a research note on Wednesday, December 18th. They set a “buy” rating and a $11.00 target price on the stock. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $7.40.

Hedge Funds Weigh In On SOPHiA GENETICS

Large investors have recently made changes to their positions in the business. Principal Financial Group Inc. grew its position in SOPHiA GENETICS by 6.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company’s stock valued at $5,290,000 after purchasing an additional 86,764 shares during the last quarter. Banque Cantonale Vaudoise lifted its stake in shares of SOPHiA GENETICS by 300.0% in the second quarter. Banque Cantonale Vaudoise now owns 12,000 shares of the company’s stock worth $55,000 after buying an additional 9,000 shares in the last quarter. Green Alpha Advisors LLC purchased a new stake in shares of SOPHiA GENETICS during the third quarter valued at approximately $79,000. Finally, Federated Hermes Inc. increased its position in shares of SOPHiA GENETICS by 57.5% during the second quarter. Federated Hermes Inc. now owns 63,000 shares of the company’s stock valued at $289,000 after acquiring an additional 23,000 shares in the last quarter. 31.59% of the stock is currently owned by hedge funds and other institutional investors.

SOPHiA GENETICS Stock Up 5.3 %

Shares of NASDAQ SOPH traded up $0.17 during mid-day trading on Friday, hitting $3.36. 63,955 shares of the stock traded hands, compared to its average volume of 62,102. The company has a market cap of $219.66 million, a price-to-earnings ratio of -3.08 and a beta of 0.99. The stock has a fifty day moving average price of $3.39 and a 200-day moving average price of $3.83. SOPHiA GENETICS has a 52 week low of $2.70 and a 52 week high of $7.37. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.59 and a current ratio of 3.80.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its earnings results on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). SOPHiA GENETICS had a negative net margin of 110.71% and a negative return on equity of 55.06%. The business had revenue of $15.85 million for the quarter, compared to the consensus estimate of $15.90 million. During the same quarter last year, the firm posted ($0.21) EPS. Research analysts anticipate that SOPHiA GENETICS will post -0.98 EPS for the current year.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.